None listed
Conditions
Brief summary
The purpose of this study is to review the use of Vinorelbine as a chemotherapy treatment option in patients post immunotherapy for metastatic non-small cell lung cancer (NSCLC). Who is it for? You may be eligible for this study if you, have received immunotherapy for metastatic NSCLC and are a patient at one of the participating sites. Study details Participants in this study will continue to receive routine clinical care, which will not be impacted by involvement in this study. Enrolled participants will have clinical data collected at one time point from their medical record. Data will be collected on the tolerability and duration of Vinorelbine chemotherapy when used following immunotherapy treatment in patients with metastatic NSCLC. It is hoped this research will offer insight into the use of Vinorelbine as a potentially beneficial treatment option for patients with metastatic NSCLC in the post immunotherapy setting.
Interventions
AVAL is a secondary data use, non interventional study that aims to describe the clinical and tumour characteristics and, treatment details of patients with metastatic non-small cell lung cancer, who have received Vinorelbine chemotherapy in the post immunotherapy setting. Data will be collected at single time point from participating Australian public hospitals and private practice from 1st Jan 2020 to 31 Dec 2021.
Sponsors
The Walter Eliza Hall Institute for Medical Research
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Patients receiving Vinorelbine chemotherapy for metastatic non small cell lung cancer post immunotherapy. 2. Treating clinician is able to provide comprehensive clinicopathological and treatment data.
Exclusion criteria
None
Outcome results
None listed